The Time Course of Repolarization Effects of Intravenous Dofetilide: A Pure Class III Antiarrhythmic Agent
•Dofetilide administered intravenously has a rapid onset of action and the dose of dofetilide is proportional to the prolongation in cardiac repolarization as represented by an increase in QTc interval.•These findings suggest the potential clinical utility of an IV formulation of dofetilide. Dofetil...
Saved in:
Published in | The American journal of cardiology Vol. 257; pp. 38 - 42 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
15.12.2025
|
Online Access | Get full text |
ISSN | 0002-9149 1879-1913 |
DOI | 10.1016/j.amjcard.2025.07.040 |
Cover
Loading…
Abstract | •Dofetilide administered intravenously has a rapid onset of action and the dose of dofetilide is proportional to the prolongation in cardiac repolarization as represented by an increase in QTc interval.•These findings suggest the potential clinical utility of an IV formulation of dofetilide.
Dofetilide’s action is inhibition of the potassium channel (IKr) which causes a delay of repolarization as seen on the ECG as QTc prolongation and is its mechanism of antiarrhythmic action. Thus, the time to repolarization prolongation is critical in evaluating the onset of potential antiarrhythmic action. To determine the extent and time course of Dofetilide administered intravenously on cardiac repolarization. Methods: Dofetilide naive healthy subjects 18–45 years received a single dose of 500 mcg dofetilide administered IV over 2.5 hours by constant infusion rate. 12-lead digital Holters recorded the ECG and 20 blood samples were collected. A validated liquid chromatographic method measured dofetilide plasma concentration. The QT intervals were measured by the median beat method from 10‑sec recordings. The Bazett formula was used for QT correction (QTc). Dofetilide concentration continuously increased from the start to the end of the infusion, then gradually decreased. The QTc showed similar dynamics with very early prolongation. At 15 min 50 mcg dofetilide was administered, 1 tenth the recommended dose, with the QTc increasing by 11 ± 10 ms (p = 0.001) indicating early effect on repolarization. There was a strong linear correlation between dofetilide concentrations and QTc intervals (r = 0.95, p < 0.001) with every 1 nanogram increase in plasma concentration resulting in a 17 ms QTc prolongation. The early effect of IV dofetilide on cardiac repolarization suggests dofetilide clinically utility with an immediate antiarrhythmic action. Future clinical studies are indicated to determine optimum dosing, efficacy as well as safety.
[Display omitted] |
---|---|
AbstractList | •Dofetilide administered intravenously has a rapid onset of action and the dose of dofetilide is proportional to the prolongation in cardiac repolarization as represented by an increase in QTc interval.•These findings suggest the potential clinical utility of an IV formulation of dofetilide.
Dofetilide’s action is inhibition of the potassium channel (IKr) which causes a delay of repolarization as seen on the ECG as QTc prolongation and is its mechanism of antiarrhythmic action. Thus, the time to repolarization prolongation is critical in evaluating the onset of potential antiarrhythmic action. To determine the extent and time course of Dofetilide administered intravenously on cardiac repolarization. Methods: Dofetilide naive healthy subjects 18–45 years received a single dose of 500 mcg dofetilide administered IV over 2.5 hours by constant infusion rate. 12-lead digital Holters recorded the ECG and 20 blood samples were collected. A validated liquid chromatographic method measured dofetilide plasma concentration. The QT intervals were measured by the median beat method from 10‑sec recordings. The Bazett formula was used for QT correction (QTc). Dofetilide concentration continuously increased from the start to the end of the infusion, then gradually decreased. The QTc showed similar dynamics with very early prolongation. At 15 min 50 mcg dofetilide was administered, 1 tenth the recommended dose, with the QTc increasing by 11 ± 10 ms (p = 0.001) indicating early effect on repolarization. There was a strong linear correlation between dofetilide concentrations and QTc intervals (r = 0.95, p < 0.001) with every 1 nanogram increase in plasma concentration resulting in a 17 ms QTc prolongation. The early effect of IV dofetilide on cardiac repolarization suggests dofetilide clinically utility with an immediate antiarrhythmic action. Future clinical studies are indicated to determine optimum dosing, efficacy as well as safety.
[Display omitted] Dofetilide's action is inhibition of the potassium channel (IKr) which causes a delay of repolarization as seen on the ECG as QTc prolongation and is its mechanism of antiarrhythmic action. Thus, the time to repolarization prolongation is critical in evaluating the onset of potential antiarrhythmic action. To determine the extent and time course of Dofetilide administered intravenously on cardiac repolarization. Methods: Dofetilide naive healthy subjects 18-45 years received a single dose of 500 mcg dofetilide administered IV over 2.5 hours by constant infusion rate. 12-lead digital Holters recorded the ECG and 20 blood samples were collected. A validated liquid chromatographic method measured dofetilide plasma concentration. The QT intervals were measured by the median beat method from 10‑sec recordings. The Bazett formula was used for QT correction (QTc). Dofetilide concentration continuously increased from the start to the end of the infusion, then gradually decreased. The QTc showed similar dynamics with very early prolongation. At 15 min 50 mcg dofetilide was administered, 1 tenth the recommended dose, with the QTc increasing by 11 ± 10 ms (p = 0.001) indicating early effect on repolarization. There was a strong linear correlation between dofetilide concentrations and QTc intervals (r = 0.95, p < 0.001) with every 1 nanogram increase in plasma concentration resulting in a 17 ms QTc prolongation. The early effect of IV dofetilide on cardiac repolarization suggests dofetilide clinically utility with an immediate antiarrhythmic action. Future clinical studies are indicated to determine optimum dosing, efficacy as well as safety. |
Author | Somberg, John C. Molnar, Janos |
Author_xml | – sequence: 1 givenname: Janos surname: Molnar fullname: Molnar, Janos – sequence: 2 givenname: John C. orcidid: 0000-0002-4518-6203 surname: Somberg fullname: Somberg, John C. email: johnsomberg1@comcast.net |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40769288$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkNFq2zAUhsXoaNKuj7ChF7AnybZkD8YIWdcaCi0jvRaKdLTIs6UgOYX06eeQtBe96a7EQf__cc53gc588IDQZ0pySij_2uVq6LSKJmeEVTkROSnJBzSntWgy2tDiDM0JISxraNnM0EVK3TRSWvFzNCuJ4A2r6znqVhvAKzcAXoZdTICDxb9hG3oV3bMaXfD42lrQYzr8tH6M6gl82CX8M1gYXe8MfMML_LCLE6JXKeG2bfHCj07FuNmPm8FpvPgDfvyEPlrVJ7g6vZfo8df1anmb3d3ftMvFXaZZRceMC1pbZk3JuFGNIZqtCTXcUiWqoqZa1YJqwWteMGWUWBe6XAvRNJqrShfGFpfoy5G73a0HMHIb3aDiXr4cPQWqY0DHkFIE-xqhRB7kyk6e5MqDXEmEnOROvR_HHkzbPzmIMmkHXoNxcTIkTXDvEr6_IejeeadV_xf2_9H_B4c6mZk |
Cites_doi | 10.1016/0002-9149(86)90692-2 10.1111/j.1365-2125.1991.tb05572.x 10.1097/00005344-199220002-00015 10.1016/S0002-9149(99)00927-3 10.1016/S0735-1097(96)00506-2 10.1161/CIRCULATIONAHA.106.180200 10.3390/jcm13206094 10.1046/j.1365-2125.2000.00243.x 10.1159/000316050 10.1016/j.vascn.2005.07.002 10.1046/j.1365-2125.2002.01627.x 10.1592/phco.20.9.776.35208 10.1016/0002-9149(92)90295-A |
ContentType | Journal Article |
Copyright | 2025 Elsevier Inc. Copyright © 2025 Elsevier Inc. All rights reserved. |
Copyright_xml | – notice: 2025 Elsevier Inc. – notice: Copyright © 2025 Elsevier Inc. All rights reserved. |
DBID | AAYXX CITATION NPM |
DOI | 10.1016/j.amjcard.2025.07.040 |
DatabaseName | CrossRef PubMed |
DatabaseTitle | CrossRef PubMed |
DatabaseTitleList | PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1879-1913 |
EndPage | 42 |
ExternalDocumentID | 40769288 10_1016_j_amjcard_2025_07_040 S0002914925004503 |
Genre | Journal Article |
GroupedDBID | --- --K --M .1- .FO .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 23M 4.4 457 4G. 5RE 5VS 6J9 7-5 71M 7RV 7X7 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAQFI AATTM AAWTL AAXKI AAXUO ABBQC ABFNM ABJNI ABLJU ABMAC ABMZM ABOCM ABPPZ ACDAQ ACGFO ACGFS ACIEU ACIUM ACIWK ACPRK ACRLP ACVFH ADBBV ADCNI ADEZE ADFRT ADUKH AEBSH AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRAH AFRHN AFTJW AFXIZ AGCQF AGHFR AGUBO AGYEJ AHMBA AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AXJTR BENPR BKOJK BKOMP BLXMC BNPGV CS3 EBS EFJIC EFKBS EO9 EP2 EP3 EX3 F5P FDB FIRID FNPLU FYGXN G-Q GBLVA IH2 IHE J1W J5H K-O KOM L7B M2O MO0 N9A O-L O9- OA. OAUVE OL~ OZT P-8 P-9 P2P PC. Q38 ROL RPZ SDF SDG SEL SES SJN SPCBC SSH SSZ T5K TWZ UNMZH UV1 WH7 WOW YFH YOC YZZ Z5R ~G- EFLBG .55 .GJ 1CY 3O- 53G 88E 8FI 8FJ 8G5 AAQQT AAQXK AAYWO AAYXX ABUWG ABWVN ABXDB ACRPL ADMUD ADNMO AFFNX AFKRA AGQPQ AHHHB ASPBG AVWKF AZFZN AZQEC BKEYQ BPHCQ BVXVI CCPQU CITATION DWQXO EJD EMOBN FEDTE FGOYB FYUFA G-2 GNUQQ GUQSH HEB HMCUK HMK HMO HVGLF HZ~ M1P M29 M41 NAPCQ OHT OVD PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO R2- SAE SV3 TEORI UKHRP WUQ X7M XPP YQJ YYP ZGI ZXP NPM |
ID | FETCH-LOGICAL-c251t-6718f2fd426da9d0c2b01d6f1a75381ca871c768632ada7b3c4b7799c6a5c3df3 |
IEDL.DBID | .~1 |
ISSN | 0002-9149 |
IngestDate | Thu Aug 28 04:49:10 EDT 2025 Wed Sep 03 16:40:38 EDT 2025 Sat Sep 06 17:21:13 EDT 2025 Sat Aug 30 06:04:46 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Language | English |
License | Copyright © 2025 Elsevier Inc. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c251t-6718f2fd426da9d0c2b01d6f1a75381ca871c768632ada7b3c4b7799c6a5c3df3 |
ORCID | 0000-0002-4518-6203 |
PMID | 40769288 |
PageCount | 5 |
ParticipantIDs | pubmed_primary_40769288 crossref_primary_10_1016_j_amjcard_2025_07_040 elsevier_sciencedirect_doi_10_1016_j_amjcard_2025_07_040 elsevier_clinicalkey_doi_10_1016_j_amjcard_2025_07_040 |
PublicationCentury | 2000 |
PublicationDate | 2025-12-15 |
PublicationDateYYYYMMDD | 2025-12-15 |
PublicationDate_xml | – month: 12 year: 2025 text: 2025-12-15 day: 15 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | The American journal of cardiology |
PublicationTitleAlternate | Am J Cardiol |
PublicationYear | 2025 |
Publisher | Elsevier Inc |
Publisher_xml | – name: Elsevier Inc |
References | Sedgwick, Rasmussen, Cobbe (bib0011) 1992; 70 FDA Guidance for Industry E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Accessed June 9, 2025. Ollerstam, Visser, Persson, Eklund, Nilsson, Forsberg, Wiklund, Gabrielsson, Duker, Al-Saffa (bib0015) 2006; 53 Tikosyn_Product_Monograph. Accessed June 9, 2025. Șorodoc, Indrei, Dobroghii, Asaftei, Ceasovschih, Constantin, Lionte, Morărașu, Diaconu, Șorodoc (bib0001) 2024; 13 Sedgwick, Rasmussen, Walker, Cobbe (bib0010) 1991; 31 Rasmussen, Allen, Blackburn, Butrous, Dalrymple (bib0014) 1992; 20 TIKOSYN – dofetilide- Drug product label. Accessed June 9, 2025 . Falk, Pollak, Singh, Friedrich (bib0017) 1997; 29 (bib0009) 2007; 115 Shah (bib0013) 2002; 54 Somberg, Preston, Ranade, Molnar (bib0003) 2010; 116 Allen, Nichols, Oliver (bib0007) 2000; 50 Lindeboom, Kingma, Crijns, Dunselman (bib0016) 2000; 85 Wang, Bergstrand, Thompson, Siddoway, Duff, Woosley, Roden (bib0004) 1986; 57 Lenz, Hilleman (bib0006) 2000; 20 BETAPACE- sotalol hydrochloride tablet – Drug product label. Accessed June 9, 2025. Lindeboom (10.1016/j.amjcard.2025.07.040_bib0016) 2000; 85 10.1016/j.amjcard.2025.07.040_bib0005 Shah (10.1016/j.amjcard.2025.07.040_bib0013) 2002; 54 10.1016/j.amjcard.2025.07.040_bib0002 Allen (10.1016/j.amjcard.2025.07.040_bib0007) 2000; 50 10.1016/j.amjcard.2025.07.040_bib0008 Sedgwick (10.1016/j.amjcard.2025.07.040_bib0010) 1991; 31 Falk (10.1016/j.amjcard.2025.07.040_bib0017) 1997; 29 (10.1016/j.amjcard.2025.07.040_bib0009) 2007; 115 10.1016/j.amjcard.2025.07.040_bib0012 Ollerstam (10.1016/j.amjcard.2025.07.040_bib0015) 2006; 53 Somberg (10.1016/j.amjcard.2025.07.040_bib0003) 2010; 116 Rasmussen (10.1016/j.amjcard.2025.07.040_bib0014) 1992; 20 Wang (10.1016/j.amjcard.2025.07.040_bib0004) 1986; 57 Lenz (10.1016/j.amjcard.2025.07.040_bib0006) 2000; 20 Șorodoc (10.1016/j.amjcard.2025.07.040_bib0001) 2024; 13 Sedgwick (10.1016/j.amjcard.2025.07.040_bib0011) 1992; 70 |
References_xml | – reference: Tikosyn_Product_Monograph. Accessed June 9, 2025. – volume: 20 start-page: S96 year: 1992 end-page: S105 ident: bib0014 article-title: Dofetilide, a novel class III antiarrhythmic agent publication-title: J Cardiovasc Pharmacol – reference: BETAPACE- sotalol hydrochloride tablet – Drug product label. Accessed June 9, 2025. – volume: 53 start-page: 174 year: 2006 end-page: 183 ident: bib0015 article-title: Pharmacokinetic-pharmacodynamic modeling of drug-induced effect on the QT interval in conscious telemetered dogs publication-title: J Pharmacol Toxicol Methods – volume: 54 start-page: 188 year: 2002 end-page: 202 ident: bib0013 article-title: The significance of QT interval in drug development publication-title: Br J Clin Pharmacol – volume: 85 start-page: 1031 year: 2000 end-page: 1033 ident: bib0016 article-title: Efficacy and safety of intravenous dofetilide for rapid termination of atrial fibrillation and atrial flutter publication-title: Am J Cardiol – volume: 115 start-page: 1306 year: 2007 end-page: 1324 ident: bib0009 article-title: Recommendations for the standardization and interpretation of the electrocardiogram: part I: the electrocardiogram and its technology: a scientific Statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society endorsed by the International Society for Computerized Electrocardiology publication-title: Circulation – reference: . – volume: 116 start-page: 219 year: 2010 end-page: 225 ident: bib0003 article-title: QT prolongation and serum sotalol concentration are highly correlated following intravenous and oral sotalol publication-title: Cardiology – volume: 13 start-page: 6094 year: 2024 ident: bib0001 article-title: Amiodarone therapy: updated practical insights publication-title: J Clin Med – volume: 50 start-page: 247 year: 2000 end-page: 253 ident: bib0007 article-title: The pharmacokinetics and pharmacodynamics of oral dofetilide after twice daily and three times daily dosing publication-title: Br J Clin Pharmacol – volume: 31 start-page: 515 year: 1991 end-page: 519 ident: bib0010 article-title: Pharmacokinetic and pharmacodynamic effects of UK-68,798, a new potential class III antiarrhythmic drug publication-title: Br J Clin Pharmacol – reference: FDA Guidance for Industry E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Accessed June 9, 2025. – volume: 20 start-page: 776 year: 2000 end-page: 786 ident: bib0006 article-title: Dofetilide, a new class III antiarrhythmic agent publication-title: Pharmacotherapy – reference: TIKOSYN – dofetilide- Drug product label. Accessed June 9, 2025 – volume: 57 start-page: 1160 year: 1986 end-page: 1165 ident: bib0004 article-title: Concentration-dependent pharmacologic properties of sotalol publication-title: Am J Cardiol – volume: 29 start-page: 385 year: 1997 end-page: 390 ident: bib0017 article-title: Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous dofetilide investigators publication-title: J Am Coll Cardiol – volume: 70 start-page: 1432 year: 1992 end-page: 1437 ident: bib0011 article-title: Effects of the class III antiarrhythmic drug dofetilide on ventricular monophasic action potential duration and QT interval dispersion in stable angina pectoris publication-title: Am J Cardiol – volume: 57 start-page: 1160 issue: 13 year: 1986 ident: 10.1016/j.amjcard.2025.07.040_bib0004 article-title: Concentration-dependent pharmacologic properties of sotalol publication-title: Am J Cardiol doi: 10.1016/0002-9149(86)90692-2 – volume: 31 start-page: 515 issue: 5 year: 1991 ident: 10.1016/j.amjcard.2025.07.040_bib0010 article-title: Pharmacokinetic and pharmacodynamic effects of UK-68,798, a new potential class III antiarrhythmic drug publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.1991.tb05572.x – volume: 20 start-page: S96 issue: Suppl 2 year: 1992 ident: 10.1016/j.amjcard.2025.07.040_bib0014 article-title: Dofetilide, a novel class III antiarrhythmic agent publication-title: J Cardiovasc Pharmacol doi: 10.1097/00005344-199220002-00015 – volume: 85 start-page: 1031 issue: 8 year: 2000 ident: 10.1016/j.amjcard.2025.07.040_bib0016 article-title: Efficacy and safety of intravenous dofetilide for rapid termination of atrial fibrillation and atrial flutter publication-title: Am J Cardiol doi: 10.1016/S0002-9149(99)00927-3 – ident: 10.1016/j.amjcard.2025.07.040_bib0008 – volume: 29 start-page: 385 issue: 2 year: 1997 ident: 10.1016/j.amjcard.2025.07.040_bib0017 article-title: Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous dofetilide investigators publication-title: J Am Coll Cardiol doi: 10.1016/S0735-1097(96)00506-2 – volume: 115 start-page: 1306 issue: 10 year: 2007 ident: 10.1016/j.amjcard.2025.07.040_bib0009 publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.106.180200 – volume: 13 start-page: 6094 issue: 20 year: 2024 ident: 10.1016/j.amjcard.2025.07.040_bib0001 article-title: Amiodarone therapy: updated practical insights publication-title: J Clin Med doi: 10.3390/jcm13206094 – ident: 10.1016/j.amjcard.2025.07.040_bib0005 – volume: 50 start-page: 247 issue: 3 year: 2000 ident: 10.1016/j.amjcard.2025.07.040_bib0007 article-title: The pharmacokinetics and pharmacodynamics of oral dofetilide after twice daily and three times daily dosing publication-title: Br J Clin Pharmacol doi: 10.1046/j.1365-2125.2000.00243.x – volume: 116 start-page: 219 issue: 3 year: 2010 ident: 10.1016/j.amjcard.2025.07.040_bib0003 article-title: QT prolongation and serum sotalol concentration are highly correlated following intravenous and oral sotalol publication-title: Cardiology doi: 10.1159/000316050 – ident: 10.1016/j.amjcard.2025.07.040_bib0002 – volume: 53 start-page: 174 issue: 2 year: 2006 ident: 10.1016/j.amjcard.2025.07.040_bib0015 article-title: Pharmacokinetic-pharmacodynamic modeling of drug-induced effect on the QT interval in conscious telemetered dogs publication-title: J Pharmacol Toxicol Methods doi: 10.1016/j.vascn.2005.07.002 – ident: 10.1016/j.amjcard.2025.07.040_bib0012 – volume: 54 start-page: 188 issue: 2 year: 2002 ident: 10.1016/j.amjcard.2025.07.040_bib0013 article-title: The significance of QT interval in drug development publication-title: Br J Clin Pharmacol doi: 10.1046/j.1365-2125.2002.01627.x – volume: 20 start-page: 776 issue: 7 year: 2000 ident: 10.1016/j.amjcard.2025.07.040_bib0006 article-title: Dofetilide, a new class III antiarrhythmic agent publication-title: Pharmacotherapy doi: 10.1592/phco.20.9.776.35208 – volume: 70 start-page: 1432 issue: 18 year: 1992 ident: 10.1016/j.amjcard.2025.07.040_bib0011 article-title: Effects of the class III antiarrhythmic drug dofetilide on ventricular monophasic action potential duration and QT interval dispersion in stable angina pectoris publication-title: Am J Cardiol doi: 10.1016/0002-9149(92)90295-A |
SSID | ssj0001156 |
Score | 2.4902294 |
Snippet | •Dofetilide administered intravenously has a rapid onset of action and the dose of dofetilide is proportional to the prolongation in cardiac repolarization as... Dofetilide's action is inhibition of the potassium channel (IKr) which causes a delay of repolarization as seen on the ECG as QTc prolongation and is its... |
SourceID | pubmed crossref elsevier |
SourceType | Index Database Publisher |
StartPage | 38 |
Title | The Time Course of Repolarization Effects of Intravenous Dofetilide: A Pure Class III Antiarrhythmic Agent |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0002914925004503 https://dx.doi.org/10.1016/j.amjcard.2025.07.040 https://www.ncbi.nlm.nih.gov/pubmed/40769288 |
Volume | 257 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JTsMwELUQSIgLYt8rH7imzeI4MbeogBoQiANIvUWuF5GKLiopEhe-nZksLVwAccxiyxo7M2-cec-EnAfKcIgMGulnkKB40jpC8tAxnhVMMZdFJcv17p73nthNP-yvkG7DhcGyytr3Vz699Nb1nU5tzc40z5Hj6_rCQ3E9xCWl4idjEerntz-WZR6AeHgDgfHtJYunM2zL0VDBRECa6IelhifugfwYn74En-stslmjRppUA9smK2a8Q9bv6v_iu2QIs02RzUHxDLpXQyeWIrSGtLXmWdJKpvgVn6S4oftWirPSy4k1Rf6Sa3NBE_own0EXCKhpmqY0GcP3P5s9vxfPo1zRBGlYe-Tp-uqx23PqUxQcBdilcDhEH-tbDaFYS6Fd5Q9cT3PrSchUYk9JSJkUJB088KWW0SBQbBBFQiguQxVoG-yT1fFkbA4JFdZwJgGhAKxgKtbSMs3jWHt4BnvExRFpN7bLppVYRtZUkQ2z2tgZGjtzowyMfUR4Y-GsYYKC78rAnf_WMF40_LZc_tL0oJrKxRAhp-XCj-Pj_3d6QjbwCutcvPCUrBazuTkDtFIMWuVybJG1JL3t3X8CZU_nmg |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JTsMwELUQSMAFse_gA9e0WRwn5lYVUAMUcQCJm-V6EamgRSVF4sK3M5OF5QKIaxxb1tiaec-eNybkKNKWQ2QwKD8DghIo5wnFY88GTjDNfJaUKtf-Fe_dsvO7-G6GdBstDKZV1r6_8umlt66_tGtrtp_yHDW-figCLK6HuAQrfs6xOEpwa7fePvM8APLwBgPj758ynvawpR6HGlYCeGIYl0U88RDkxwD1JfqcLZOlGjbSTjWzFTJjR6tkvl9fjK-RISw3RTkHxUfoni0dO4rYGnhrLbSkVZ3iZ2zJ8ET3pazOSk_Gzhb5Q27sMe3Q6-kEhkBETbMso50ROIDJ5P61uH_MNe2gDmud3J6d3nR7Xv2MgqcBvBQeh_DjQmcgFhsljK_DgR8Y7gIFVCUNtALOpIF18ChURiWDSLNBkgihuYp1ZFy0QWZH45HdIlQ4y5kCiAK4gunUKMcMT1MT4CPsCRfbpNXYTj5V1TJkk0Y2lLWxJRpb-okEY28T3lhYNlJQcF4S_PlvHdOPjt_2y1-6blZL-TFFILVchGm68_9BD8lC76Z_KS-zq4tdsogtmPQSxHtktphM7T5Al2JwUG7Nd9VK6TA |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Time+Course+of+Repolarization+Effects+of+Intravenous+Dofetilide%3A+A+Pure+Class+III+Antiarrhythmic+Agent&rft.jtitle=The+American+journal+of+cardiology&rft.au=Molnar%2C+Janos&rft.au=Somberg%2C+John+C.&rft.date=2025-12-15&rft.pub=Elsevier+Inc&rft.issn=0002-9149&rft.volume=257&rft.spage=38&rft.epage=42&rft_id=info:doi/10.1016%2Fj.amjcard.2025.07.040&rft.externalDocID=S0002914925004503 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0002-9149&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0002-9149&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0002-9149&client=summon |